Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ataciguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 13/20 | 0.64 |
| ▸ | MEN1 | O00255 | 12/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | HTT | P42858 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ataciguat SCHEMBL491675 | 1.00 | KMT2A (0.64) | KMT2AMEN1MAPTHTTLMNA | |
| Ataciguat SCHEMBL492158 | 0.99 | KMT2A (0.63) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL13297364 | 0.91 | KMT2A (0.62) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL10252896 | 0.91 | ALDH1A1 (0.58) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL29424222 | 0.89 | KMT2A (0.76) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL492486 | 0.89 | KMT2A (0.59) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL491931 | 0.88 | KMT2A (0.72) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL491936 | 0.87 | KMT2A (0.61) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL491874 | 0.87 | KMT2A (0.63) | KMT2AMEN1MAPTHTTLMNA | |
| SCHEMBL492533 | 0.86 | KMT2A (0.60) | KMT2AMEN1MAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| US-20250281485-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | UNIVERSITEIT MAASTRICHT (NL) | 2025-09-11 | — | — | US | claimed |
| US-20250205276-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE USING COMBINATION OF A NITRODILATOR AND A NITROGEN OXIDE COMPOUND | LOMA LINDA UNIVERSITY (US) | 2025-06-26 | — | — | US | claimed |
| EP-4511017-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | Universiteit Maastricht (NL) | 2025-02-26 | — | — | EP | claimed |
| EP-4489739-A2 | COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE USING COMBINATION OF A NITRODILATOR AND A NITROGEN OXIDE COMPOUND | Loma Linda University (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023204698-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | UNIVERSITEIT MAASTRICHT (NL) | 2023-10-26 | — | — | WO | claimed |
| WO-2023173141-A2 | COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE USING COMBINATION OF A NITRODILATOR AND A NITROGEN OXIDE COMPOUND | LOMA LINDA UNIVERSITY (US) | 2023-09-14 | — | — | WO | claimed |
| US-20230087609-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-23 | — | — | US | claimed |
| US-20230083417-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-16 | — | — | US | claimed |
| EP-4110396-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | Universiteit Maastricht (NL) | 2023-01-04 | — | — | EP | claimed |
| EP-4106741-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR OR OF A COMBINATION OF A SGC STIMULATOR AND AN SGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF SGC IS OXIDIZED OR WHEREIN SGC IS DEFICIENT IN HEME | Universiteit Maastricht (NL) | 2022-12-28 | — | — | EP | claimed |
| US-20220362256-A1 | DISRUPTION OF VASCULAR SMOOTH MUSCLE RELAXATION BY CARFILZOMIB MAY BE THE PRIMARY REASON FOR CFZ-INDUCED VASCULAR DYSFUNCTION | AMGEN INC. | 2022-11-17 | — | — | US | claimed |
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| CN-114144229-A | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | 梅约医学教育与研究基金会 | 2022-03-04 | — | — | CN | claimed |
| US-20220062307-A1 | METHODS AND MATERIALS FOR TREATING CALCIFIC AORTIC VALVE STENOSIS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-03-03 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022023960-A1 | METHODS OF TREATING AND PREVENTING CORONAVIRUS INFECTION AND DISRUPTING CORONAVIRUS REPLICATION | FUNDACIÓN UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2022-02-03 | — | — | WO | claimed |
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2022023960-A1 | METHODS OF TREATING AND PREVENTING CORONAVIRUS INFECTION AND DISRUPTING CORONAVIRUS REPLICATION | FUNDACIÓN UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | PDE5A, PRKG2, MAPKAPK5 | KMT2A 1038/4885MEN1 2488/4885MAPT 2065/4885 |
| US-20250281485-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | NOX5, PDE5A, NOX1 | KMT2A 2651/4885MEN1 4160/4885MAPT 4214/4885 |
| US-20230087609-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | GUCY1A1, GUCY1B1, GUCY1A2 | KMT2A 3971/4885MEN1 2923/4885MAPT 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.